Articles tagged with Gliomas
Researchers have discovered that combining tricyclic antidepressants with anticoagulant drugs can slow down glioma tumors in mice by causing excessive autophagy. The study, published in Cancer Cell, found that the combination therapy doubled the lifespan of mice with gliomas.
A study published in Neurosurgery found that complete resection of high-grade brain cancer significantly improves survival rates in children. The study revealed a greater survival benefit for female patients compared to male patients. Gross total resection (GTR) improved the chances of survival free of recurrent or progressive cancer o...
A UBC study suggests targeting healthy cells around tumors to stop brain cancer from spreading. The research team found that glioma cells can hijack astrocytes, regulating their environment to stimulate tumor growth and invasion.
Erlangen-based doctors have created a new classification system for brain tumors that predicts the development of gliomas with high precision. The Friedlein Grading A/B (FGA/B) system classifies tumors according to their position in the brain on routine MRI scans.
Researchers found improved median survival of patients with low-grade gliomas increasing from 44 months to 57 months between 1999 and 2010. The study suggests more effective chemotherapies contribute to the increased survival, despite a decrease in radiation therapy use.
A national cancer study has found that a tumor's DNA, not just tumor stage, is key to determining if a lower-grade malignant brain tumor may rapidly progress to glioblastoma. The findings could lead to earlier and more aggressive treatment for those tumors projected to be on the fast path.
A UCSF-Mayo Clinic team has identified three molecular markers that can classify gliomas more accurately than current methods. The study found that these markers are associated with distinct subgroups of gliomas varying in median survival times and characteristics.
Researchers at Mayo Clinic have developed a new molecular classification system for gliomas, which could lead to more accurate diagnoses and personalized treatments. The system categorizes tumors based on three genetic alterations, allowing clinicians to predict patient outcomes and tailor treatment plans accordingly.
A groundbreaking study reclassifies brain tumors using molecular diagnostics, surpassing traditional microscopic classification. The findings will enable more consistent diagnosis and treatment of diffuse gliomas, guiding patient management and informing chemotherapy strategies.
A new way of classifying brain cancers has been found, with striking molecular differences between various forms of gliomas. This discovery could lead to more precise diagnosis and patient management.
A new Stanford University School of Medicine study has found that brain tumor growth is stimulated by nerve activity in the cerebral cortex. The research, conducted in mice with human brain cancer implants, identified a specific protein called neuroligin-3 as responsible for the increase in tumor growth associated with neuronal activity.
Researchers at Tel Aviv University have developed a groundbreaking strategy to stop brain tumor cell proliferation with targeted nanoparticles. The therapy uses RNA genetic interference to silence key proteins involved in cell division, resulting in promising survival rates for mouse models.
Research found a statistically significant association between long-term hormonal contraceptive use and glioma risk in women aged 15-49. The study suggests that taking hormonal contraceptives for at least five years may increase the risk of developing a rare brain tumor, glioma.
Researchers have identified a gene associated with familial glioma, suggesting that certain individuals may be genetically predisposed to the disease. The POT1 gene mutation is linked to lower-grade oligodendroglioma, which is more sensitive to radiation therapy, and raises hopes for improved treatments and preventive strategies.
Researchers at Case Western Reserve University have been awarded a $250,000 grant to study the use of nanotechnology in treating pediatric glioma brain tumors. The team aims to develop targeted and less toxic treatment strategies for this devastating disease.
Brain tumors use a stealth approach to evade the body's defense forces by coating their cells with extra amounts of galectin-1, a protein that evades detection by the early-warning immune system. Blocking this protein could potentially help patients by enabling the innate immune system to recognize and attack early-stage cancer growth.
Researchers found that malignant astrocytoma patients with the IDH1 mutation benefit greatly from surgical removal of as much tumor tissue as possible. This approach significantly improves survival, with average patient survival rates of 13.5 years for those with mutant tumors compared to less than 1.5 years for non-mutant tumors.
Researchers have found that an experimental drug targeting tumor-associated macrophages decreases glioblastoma growth and extends the survival of laboratory mice with the cancer. The treatment increases rates of programmed cell death in both the macrophages and tumor cells, leading to reduced tumor proliferation and increased survival.
Researchers at Children's National Hospital have discovered two distinct subtypes of pediatric diffuse intrinsic pontine gliomas (DIPGs), a type of brain stem tumor that is almost always lethal. The study found that these subtypes are associated with poorer overall survival rates, particularly for patients with histone 3 mutations.
Researchers found that hyperthermia treatment completely destroyed the blood-brain barrier surrounding tumors, allowing chemotherapy drugs to target and kill cancer cells. Additionally, hyperthermia combined with radiotherapy showed synergistic benefits in treating brain gliomas.
Researchers at Johns Hopkins Medicine found that the mammalian target of rapamycin (mTOR) pathway is active in many difficult-to-treat pediatric brain tumors, offering a potential new target for treatment. Blocking this pathway with an experimental drug reduced tumor growth by up to 73% in laboratory studies.
A meta-analysis found that the XRCC1 Arg399Gln polymorphism is associated with an increased risk of glioma, especially in Asian populations. The study suggests that this genetic variation may serve as a biomarker for glioma susceptibility and provide scientific basis for population screening.
Researchers found that human umbilical cord mesenchymal stem cells demonstrate excellent glioma-specific targeting capacity after intratumoral injection or contralateral ventricular administration in vivo. These findings suggest a promising therapeutic strategy for glioblastoma treatment.
Transplantation of neural stem cells into tumor-bearing rats inhibits abnormal Ras/Raf/Mek/Erk signaling, promoting apoptosis and potentially treating glioma. This study provides insights into the therapeutic effects of neural stem cell transplantation on glioma in mice.
Researchers found gliomas produce quinolinic acid, a metabolite of tryptophan, to generate NAD+, evading cell death. A new enzyme, QRPT, enables this process, potentially leading to therapy resistance.
A study at Ohio State University Comprehensive Cancer Center identified a mesenchymal subtype of glioblastoma as the most aggressive and lethal form of brain cancer. The mesenchymal subtype is characterized by high levels of the enzyme ALDH1A3, which drives tumor growth and resistance to radiation.
A new drug has shown significant promise in extending survival when used in combination with radiation therapy for brain cancer patients. The experimental drug, KU-60019, blocks the activation of ATM kinase, leading to enhanced destruction of glioma cells.
Researchers found a specific MYBL1 gene mutation in nearly 30% of diffuse low-grade gliomas, which may help diagnose and guide treatment. The mutated gene can cause tumors in mice, providing new leads for investigation into its function and potential diagnostic test.
Researchers identified ELTD1 as a promising biomarker for diagnosing gliomas, particularly high-grade glioblastoma multiforme (GBM). Studies found that ELTD1 levels were strongly associated with glioma development and prognosis.
Researchers found ID proteins essential for retaining glioma-initiating cells in a specific extracellular niche, maintaining their cancer-promoting properties. The study's results suggest ID proteins as potential therapeutic targets for glioma treatment.
Researchers at Barrow Neurological Institute found that a ketogenic diet significantly enhances the anti-tumor effect of radiation, leading to improved survival rates for mice with malignant gliomas. The study suggests that the diet could be used as an adjuvant therapy without FDA approval.
Researchers used PET imaging to evaluate tumor grade and cellular proliferation in patients with gliomas. The study found that F-18-FLT PET provided a more comprehensive view of tumor grade and correlated with overall survival, making it a valuable tool for guiding treatment.
Moffitt Cancer Center researchers have identified novel metabolic signatures in glioma, a type of tumor that starts in the brain. These findings may pave the way for personalized therapy and prognostic value.
Researchers at Barrow Neurological Institute and Arizona State University have made a breakthrough in understanding why brain tumors are difficult to treat. The study reveals that the immune system behaves differently in different regions of the brain, including tumors, leading to potential limitations in effective treatment.
A new study found that individuals with allergies had a significantly lower risk of developing glioma, a type of brain tumor. Women were more likely to benefit from this reduced risk, with those testing positive for elevated allergen-specific IgE experiencing a 54% decrease in glioblastoma risk.
Researchers found that neural precursor cells protect the young brain against high-grade gliomas, especially glioblastoma, by inducing stress-induced cell-death in tumor cells. The cells release substances that activate TRPV1 ion channels in the tumor cells, leading to their death.
Scientists at Washington University School of Medicine found that stem cells from a specific part of the developing brain contribute to brain tumors caused by neurofibromatosis type 1. The study suggests that understanding the unique characteristics of these stem cells may lead to more effective treatments for pediatric brain tumors.
A recent study at Moffitt Cancer Center has validated a rare genetic variant associated with an increased risk of glioma, the most common and lethal type of brain tumor. The study found that individuals carrying this variant had a 3.5 times higher risk of developing glioma, but also experienced a 50% reduction in death rates
A new PET imaging technique using an amino acid probe can predict the effectiveness of brain cancer treatment as early as two weeks after initiation, without requiring invasive biopsies. This method provides vital information about the body's response to therapy and has shown promising results in patients with aggressive glioma tumors.
The RTOG 0925 study aims to identify early clinical and neurocognitive changes that could precede tumor progression in low-risk glioma patients. The study will compare treatment effects on cognitive function, quality of life, and seizure control in patients with evidence versus no evidence of progression.
Human gliomas implanted in mice were found to release excess levels of glutamate, overstimulating neurons and triggering seizures. Sulfasalazine, an anti-inflammatory drug, was shown to reduce seizures by inhibiting glutamate release from the tumor.
Researchers at UCLA found that brain cancer stem cells can change their metabolic state from glycolysis to oxidative phosphorylation, allowing them to evade treatment. This unique ability makes glioma stem cells resistant to conventional treatments, highlighting the need for new therapies targeting these cells specifically.
Researchers at Cleveland Clinic have identified a molecular pathway that promotes brain tumor growth in malignant glioma. The study found that existing medications block this pathway and delay tumor growth in animal models, suggesting a potential new treatment option.
A University of Oregon-led team has identified oligodendrocyte precursor cells (OPCs) as the cellular origin of malignant glioma, a deadly human brain cancer. The discovery was made possible by a genetic mosaic technique that allowed researchers to pinpoint the point of origin for tumor development.
Researchers have discovered an enzyme in glioblastoma stem cells that allows them to grow and seed tumors. Unlike normal stem cells, these enzymes are not shared, making them a potential target for therapy. The study found that inhibiting this pathway slows the growth of brain tumors in mice, offering hope for improved treatment options.
The IARC classified radiofrequency electromagnetic fields as possibly carcinogenic to humans based on studies that found a possible link between long-term mobile phone use and increased risk of brain tumors. Exposure limits were established, but the evidence is not yet conclusive.
A study published in the journal Cancer found that synthetic hypericin inhibited the growth of glioma cells and was well-tolerated in patients with recurrent malignant brain tumors. Forty percent of participants completed a three-month treatment regimen without adverse effects.
Researchers at UAB have discovered that blocking a specific receptor on glioma cells can starve them of nutrients, effectively stopping their invasion in the brain. The target is a drug already approved for use in Europe, which increases blood vessel size.
Researchers have successfully destroyed tumors of human brain cancer cells in animal tests using light-activated nanoparticles. The treatment showed promising results, with over half of the treated animals remaining cancer-free after three months.
A Northwestern University study found that brain cancer patients with malignant gliomas tend to overestimate their quality of life compared to their caregivers. The research suggests that caregivers play a crucial role in providing a more accurate assessment of the patient's well-being.
A new study identifies a crucial gene in pediatric high-grade glioma, which may lead to the development of more effective drugs. The research found that the PDGFRA gene is unusually active in childhood cancer and is likely to be an important drug target.
Researchers at Agios Pharmaceuticals have discovered that the mutated IDH1 gene produces a metabolite called 2-hydroxyglutarate, which contributes to the formation and progression of gliomas. This finding validates cancer metabolism as an approach to identify new ways to treat cancer.
Researchers found that physical activity in adolescence was associated with a 36% lower risk of glioma, the most common type of brain cancer. Participants who were obese during adolescence had an increased risk of glioma, while height was linked to twice the risk.
Patients who received radiotherapy for low-grade glioma brain tumors showed significant cognitive decline compared to those who did not receive treatment. The study found that attentional functioning, executive functioning, and information processing speed were lower in patients given radiotherapy. Deferring treatment or using modern r...
A large-scale study has identified genetic variations across five genes as risk factors for the development of gliomas, the most frequent type of brain tumor. The study found that individuals with certain variations have a higher risk of developing glioma, with those with eight or more variations having a three-fold increased risk.
Researchers found hypofractionated stereotactic radiotherapy improved symptoms and survival time in patients with recurrent low-grade glioma. The treatment was well-tolerated and allowed patients to complete the full course of therapy.
Scientists at Duke University Medical Center and Johns Hopkins University have identified two genes with potential as therapeutic targets for malignant glioma, a deadly class of brain tumors. IDH1 mutations were found in over 70% of astrocytomas and olidgodendrogliomas, associated with longer survival times.
Scientists have identified two gene mutations, IDH1 and IDH2, linked to nearly three-quarters of gliomas, a type of brain cancer. These mutations are associated with longer survival rates in patients with certain types of gliomas. Further research may lead to more precise diagnoses and treatments.
Researchers at the Salk Institute used fruit flies as a model to study gliomas, the most common malignant brain tumors. They found that activating specific signaling pathways in the fly brains resulted in tumor-like growths, mimicking human disease.
Patients with low-grade gliomas who underwent aggressive surgeries were free of tumor recurrence an average of 15 years after diagnosis. Radiation therapy significantly extended their survival time, with patients living up to six years without tumor recurrence.